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Abstract General lipoprotein (Lp) (a) screening can help
to identify patients at high risk for cardiovascular disease.
Non-invasive methods allow early detection of clinically
asymptomatic incipient atherosclerotic disease. Medical
treatment options are still unsatisfactory. Lp(a) apheresis
is an established treatment in Germany for secondary pre-
vention of progressive cardiovascular disease. Statin-based
lowering of LDL cholesterol and thrombocyte aggregation
inhibitors still represent the basis of medical treatment.
Target levels for LDL-cholesterol should be modified in
patients with hyperlipoproteinemia (a).
Keywords Lipoprotein (a) · Lp (a) apheresis ·
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Introduction
The role of Lp (a) as an independent risk factor is mean-
while generally accepted [1–3]. The aim of secondary pre-
vention of cardiovascular and other vascular diseases in
patients with hyperlipoproteinemia (a) is to prevent further
lethal and non-lethal complications, if an atherosclerotic
disease is already clinically manifest. Mostly the coronary
arteries, the arteries of the lower extremities and the cere-
brovascular system of patients in the second half of life are




1 2nd Medical Clinic – Nephrology, Hypertension and Vascular
Diseases, AGAPLESION Markus-Hospital, Frankfurt/Main,
Germany
involved. Primary prevention usually focuses on younger
patients without clinically symptomatic atherosclerotic dis-
ease. Statins have shown to be effective in primary preven-
tion even in patients with intermediate risk [4, 5].
The use of non-invasive diagnostic procedures as e. g.
B-mode sonography of blood vessels or cardiac computed
tomography contributes to early risk stratification. With
these techniques a continuous progression of atherosclerotic
plaques sometimes can be observed over decades in clin-
ically asymptomatic patients. Therefore primary and sec-
ondary prevention are no longer strictly discriminated.
Indication for screening of Lp (a)
As screening for lipoprotein (Lp) (a) of the general pop-
ulation is currently not yet recommended, many patients
miss early preventive strategies. For secondary prevention,
Lp (a) should be measured in premature cardiovascular dis-
ease and progressive atherosclerotic disease despite correc-
tion of all other risk factors, especially despite optimal lipid-
lowering treatment. For primary prevention, Lp (a) screen-
ing is recommended in patients with a positive family his-
tory of premature cardiovascular diseases, elevated Lp (a) in
other family members, familial hypercholesterolemia, and
in high-risk patients with a 10-year risk of fatal cardiovas-
cular disease of 5–10% according to the ESC score [6].
It should be discussed to extend Lp (a) screening to ev-
ery individual with a vascular event, which can not suffi-
ciently be explained by typical risk factors, independent of
the patient’s age. Furthermore, a high coincidence with ge-
netically induced hemostatic defects has to be considered
[7].
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Table 1 Drugs with significant effects on serum Lp(a) concentration
Substance Mode of action Reduction of Lp(a) (%) Special notes
Nicotinic acid Classical drug 20–30 Moderate side effects
Evolocumab
Alirocumab
PCSK9 antibodies 15–30 Very low side effects
Lomitapide MTP inhibitor 15–32 Risk of steatosis
Mipomersen Apo B100 antisense oligonu-
cleotide
20–35 Risk of steatosis
ISIS-APO (a) 144367 Apo (a) antisense oilgo-
nucelotide
30–80 Clinical trials still running
No drug has yet been approved for specific treatment of hyperlipoproteinemia (a)
No effect on clinical endpoints has yet been demonstrated in neither drug













<35 +++ <115 mg% – – Correct triglycerides
>35 ++ <100 mg% + 50 mg/d? 00
<60 ++ <100 mg% + 50 mg/d 00
Secondary
Prevention
<60 ++ <50 mg% ++ 100 mg/d 00
>60 + <70 mg% ++ 100 mg/d 00
Progression – + <30 mg% ++ 100 mg/d 00
(Lp(a) apheresis obligatory) Consider dual platelet inhibi-
tion, anticoagulation as last
option?
End-stage renal disease and the nephrotic syndrome are
most frequent causes of secondary hypolipoproteinemia (a)
[8, 9].
In many patients, an unexpected cardiovascular event
induces the first measurement of Lp (a) and a profound
evaluation of conventional, generally accepted risk factors;
the German lipid league proposes a general screening of
the whole population by at least one single measurement in
life. As the laboratory methods still have a high variance,
2–3 controls may be indicated, if exact risk estimation is
necessary [9, 10].
Therapeutic options in hyperlipoproteinemia (a)
Lifestyle changes and statins have no relevant effects on
serum Lp (a) concentrations. Several drugs are able to re-
duce elevated Lp (a) levels by 5–30%. However, up to now
there is no evidence of any reduction of clinical vascular
endpoints for all substances. Neither has any of these drugs
been approved by the German authorities for the treatment
of hyperlipoproteinemia (a) (Table 1).
Nicotinic acid at a daily dose of 2–3 g/die can reduce
Lp (a) levels by up to 30%. Similar results have been shown
for microsomal triglyceride transfer protein inhibitor lomi-
tapide and the apo-B-100 antisense oligonucleotide mipom-
ersen. However, both drugs bear a considerable risk of the
development of fatty liver disease, being the main reason of
failing German drug approval for the treatment of elevated
LDL-cholesterol and lipoprotein (a) levels [11–13].
Two PCSK9-antibodies have been introduced for the
treatment of severe hypercholesterolemia, refractory to con-
ventional drug combinations. In contrast to their impressive
potential on LDL-cholesterol, the influence on Lp (a) is
markedly lower; a lowering of Lp (a) levels by up to 30%
has been reported, the reduction rate is below 20% in pa-
tients with high levels of Lp (a) [14, 15].
A most promising approach is the antisense oligonu-
cleotide against apolipoprotein (a), where reduction rates
up to 80% seem possible; nevertheless, the necessary clin-
ical study protocols for drug approval have not yet been
completed [16]. Therefore, in daily practice no option for
a direct medical correction of hyperlipoproteinemia (a) is
available.
In Germany Lp (a) apheresis is an established treatment
for patients with elevated Lp (a) levels providing reduction
rates of 60–70% compared to baseline and pre-apheresis
levels. Lp (a) apheresis has been approved for secondary
prevention in patients with clinically manifest cardiovascu-
lar diseases, which is progressive despite the correction of
all other risk factors, and in patients with already extended
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cardiovascular diseases, in whom a progression is assumed
to have deleterious consequences [17].
An impressive reduction of cardiovascular complications
has been observed in five observation studies in different
German patient cohorts [18–23].
The annual quality report of the Kassenärztliche Bun-
desvereinigung of 2015 included 953 patients with isolated
hyperlipoproteinemia (a) treated with regular Lp (a) aphere-
sis [24].
Treatment of hyperlipoproteinemia (a) by
individual risk stratification
Without any effective medical treatment option for lower-
ing Lp(a)-levels, primary prevention has to focus on on the
reduction of the total individual risk for cardiovascular dis-
ease and thus on the correction of classical concomitant risk
factors which are not discussed here (Table 2).
In young and healthy patients without risk factors, even
strongly elevated Lp (a) levels to more than 3.5fold above
normal induce only a small increment of the absolute car-
diovascular risk – in spite of doubling the relative risk.
However, if other factors such ass smoking, hypertension,
male sex, age >60 years or classical Framingham risks of
>20%/10 years are present, a dramatic increment of the
absolute risk can been observed [25, 26].
But the risk of elevated Lp (a) level alone is already
comparable to the risk of smoking or arterial hypertension
in low risk situations, those being classical targets of pre-
ventive efforts in daily practice.
Further discrimination of cardiovascular risk is par-
tially possible by the measurement of the genetic variants
rs10455872 and 3798220, which determine the serum con-
centration of Lp (a) as well as the size of Lp (a) particles
by the numbers of kringle IV-type 2 copies [27].
Except for apheresis, specific recommendations for the
management of patients with hyperlipoproteinemia (a) have
not yet been established. This is explained by the lack of
therapeutics options and of clinical evidence of any differ-
entiated medical strategy.
It has been shown that the cardiovascular risk of ele-
vated of LDL cholesterol is considerably increased in the
presence of an additionally elevated Lp(a) level (a) [28, 29].
It is the current concept to establish optimal LDL-choles-
terol target levels in patients with hyperlipoproteinemia (a)
by means of dietary restrictions and the use of statins, al-
though this strategy has not yet been confirmed by clinical
endpoint studies [30].
In patients with moderate risk (score risk 1  5%), the
current ESC/EAS-guideline of 2016 recommend a target
LDL-cholesterol of <115 mg% (<3.0 mmol/l) if at least one
classical major risk factor is present (6). Although Lp(a)
is not yet accepted as a major risk factor, this target level
should be implemented for patients with elevated Lp(a)-
levels.
In patient with a 10-year risk of 5  10%, ESC/EAS-
guidelines recommend a LDL target level of <100 mg%, if
at least one further major risk factor is present. It should
be remembered that the risk difference of these 2 groups is
mainly caused by gender and age.
The use of platelet inhibition is not generally recom-
mended for primary prevention even in elderly persons [40].
As Lp (a) exerts considerable prothrombotic effects [31,
32], a primary protection can be discussed, e. g. using low
dose aspirin in adult patients >35 years of age. At least
in patients >60 years, a positive risk/benefit ratio may be
expected, if already minor evidence of vessel alterations is
present.
In patients with clinically symptomatic atherosclerotic
disease, secondary prevention regularly includes the use of
platelet inhibitors, usually aspirin at a dose of 100 mg/die
and the use of statins in order to reduce LDL-cholesterol
below a target level of 70 mg% [33–36].
In Lp(a) patients with premature cardiovascular disease
below 60 years of age, a therapeutic target of <50 mg% may
be regarded as a more safe strategy, and in patients with
advanced or progressive cardiovascular disease despite op-
timal guideline-based therapy, aggressive lowering of LDL-
cholesterol to <30 mg% as well as combined platelet inhi-
bition should be considered, as these regimens hardly bear
any clinically relevant risk [37, 38].
Apart from that, the correction of elevated serum triglyc-
erides should further contribute to a reduction of the total
cardiovascular risk [39].
In exceptional cases with advanced and recurrent vas-
cular occlusions, triple therapy including anticoagulatory
substances as vitamin K antagonists, thrombin and factor
Xa inhibitors may be advantageous [38, 40].
Conclusion
In patients with hyperlipidaemia (a) very early identifica-
tion and comprehensive risk management are mandatory
for successful cardiovascular prevention as long as a direct
and efficient medical correction is not available and Lp(a)
apheresis is not yet required.
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